Skip to main content
Explore URMC
menu

SGIM19105, Linehan, 4142-17, pancreatic and colorectal cancer, VX15/2503, ipilimumab, and nivolumab

Research Question:
How well does a monoclonal antibody, "anti-SEMA4D monoclonal antibody VX15/2503," work in treating patients with stage I-III pancreatic cancer?

Basic Study Information

Purpose:
This randomized phase I trial studies how well anti-semaphorin 4D (anti-SEMA4D) monoclonal antibody VX15/2503 with or without ipilimumab or nivolumab work in treating patients with stage I-III pancreatic cancer that can be removed by surgery or stage IV colorectal cancer that has spread to the liver and can be removed by surgery. Monoclonal antibodies, such as anti-SEMA4D monoclonal antibody VX15/2503, ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and spread.

Location: University of Rochester Medical Center
Study Reference #: SGIM19105

Lead Researcher (Principal Investigator)

Lead Researcher:  David Linehan

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Return to Search